Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

421 articles

Keyword: microRNAClear keyword
Molecular therapy. Nucleic acids2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Segmented poly(A) tails with microRNA target sites confer tissue-specific regulation for mRNA therapeutics

Qi R, Chen H, Chen R, Bao H, Sun Y, Xu R, Et Al.

Targeted delivery and controlled expression of mRNA encapsulated by lipid nanoparticles (mRNA-LNPs) are critical for the development of safe and effective mRNA medicines. However, efficient post-delivery regulation of mRNA-LNP expression remains challenging, and conventional approaches largely rely on modifying the 3' UTR at the expense of other regulatory elements. In this study, we engineered segmented poly(A) tail variants that function as gene-specific regulatory elements for synthetic mRNAs, providing an alternative regulatory module that preserves UTR integrity.

MT: non-coding RNAsmRNA therapeuticsmRNA-LNPmiRNA target sitemicroRNApoly(A)selective expression
Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.
Articles | Brilliant Blue Biosciences